Beta Blockade in Critical Injury
| Status: | Terminated |
|---|---|
| Conditions: | Hospital |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | February 15, 2006 |
| End Date: | January 31, 2009 |
Beta-blockade Reduces Catabolism in Severely Injured Trauma Patients
Critically injured patients endure a period of hypermetabolism/catabolism after being
resuscitated. The metabolic cost of this may be measured in loss of lean body mass, poor
wound healing, susceptibility to infection and long hospital stays. While there have been
some data to suggest that hypermetabolism can be ameliorated in burn patients by beta
blockade, to our knowledge, a prospective trial in trauma patients has not yet been done. Our
hypothesis is that nonselective beta blockade will reduce catabolism, improve glucose
control, blunt loss of lean body mass, decrease infections and improve outcome in a cohort of
critically injured patients.
resuscitated. The metabolic cost of this may be measured in loss of lean body mass, poor
wound healing, susceptibility to infection and long hospital stays. While there have been
some data to suggest that hypermetabolism can be ameliorated in burn patients by beta
blockade, to our knowledge, a prospective trial in trauma patients has not yet been done. Our
hypothesis is that nonselective beta blockade will reduce catabolism, improve glucose
control, blunt loss of lean body mass, decrease infections and improve outcome in a cohort of
critically injured patients.
Inclusion Criteria:
- ISS>25, stable at 48 hours after injury
- Fully resuscitated
- Ventilated
Exclusion Criteria Include:
- Intracranial hypertension requiring active treatment
- Hypotension/Pressors
- Already on beta blocker for a standard indication
We found this trial at
1
site
Denver Health Medical Center Denver Health is a comprehensive, integrated organization providing level one care...
Click here to add this to my saved trials
